270 related articles for article (PubMed ID: 35746716)
1. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
2. Utility of droplet digital PCR for the quantitative detection of polyomavirus JC in clinical samples.
Giovannelli I; Ciccone N; Vaggelli G; Malva ND; Torricelli F; Rossolini GM; Giannecchini S
J Clin Virol; 2016 Sep; 82():70-75. PubMed ID: 27454232
[TBL] [Abstract][Full Text] [Related]
3. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
4. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
6. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
7. A loop-mediated isothermal amplification assay for the detection and quantification of JC polyomavirus in cerebrospinal fluid: a diagnostic and clinical management tool and technique for progressive multifocal leukoencephalopathy.
Kinoshita H; Nakamichi K; Lim CK; Takayama-Ito M; Wang L; Iizuka I; Kurane I; Saijo M
Virol J; 2018 Aug; 15(1):136. PubMed ID: 30170628
[TBL] [Abstract][Full Text] [Related]
8. High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
Takahashi K; Sato Y; Sekizuka T; Kuroda M; Suzuki T; Hasegawa H; Katano H
PLoS Pathog; 2020 Apr; 16(4):e1008523. PubMed ID: 32324824
[TBL] [Abstract][Full Text] [Related]
9. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
10. The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML.
Rocca A; Martelli F; Delbue S; Ferrante P; Bartolozzi D; Azzi A; Giannecchini S
J Clin Virol; 2015 Sep; 70():1-6. PubMed ID: 26305810
[TBL] [Abstract][Full Text] [Related]
11. JC polyomavirus DNA detection in clinical practice.
Kartau M; Auvinen E; Verkkoniemi-Ahola A; Mannonen L; Helanterä I; Anttila VJ
J Clin Virol; 2022 Jan; 146():105051. PubMed ID: 34883406
[TBL] [Abstract][Full Text] [Related]
12. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis.
Ciardi MR; Zingaropoli MA; Iannetta M; Prezioso C; Perri V; Pasculli P; Lichtner M; d'Ettorre G; Altieri M; Conte A; Pietropaolo V; Mastroianni CM; Vullo V
Virol J; 2020 Feb; 17(1):23. PubMed ID: 32046748
[TBL] [Abstract][Full Text] [Related]
13. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
[TBL] [Abstract][Full Text] [Related]
14. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Flores J; Anguiano O; Rivas-Alonso V; González-Conchillos H; Pérez-Saldivar M; Sotelo J; Magaña-Maldonado R; Quiñones S; Corona T; Olivares H; Hernández-González O; Martínez-Palomo A; Treviño I; Ordoñez G
Mult Scler Relat Disord; 2021 Nov; 56():103266. PubMed ID: 34555758
[TBL] [Abstract][Full Text] [Related]
16. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
18. Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples.
Scribano S; Guerrini M; Arvia R; Guasti D; Nardini P; Romagnoli P; Giannecchini S
J Clin Virol; 2020 Jul; 128():104435. PubMed ID: 32442760
[TBL] [Abstract][Full Text] [Related]
19. CPT11 prevents virus replication in JCI cells persistently infected with JC polyomavirus.
Nukuzuma S; Nukuzuma C; Kameoka M; Sugiura S; Nakamichi K; Tasaki T; Takegami T
Microbiol Immunol; 2017 Jun; 61(6):232-238. PubMed ID: 28463406
[TBL] [Abstract][Full Text] [Related]
20. Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
Giovannelli I; Martelli F; Repice A; Massacesi L; Azzi A; Giannecchini S
J Neurovirol; 2015 Dec; 21(6):666-70. PubMed ID: 25678142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
